Abstract
Background Given the COVID-19 pandemic’s, researchers are beseeched for effective treatments. Herbal medicine is also queried for potential supplementary treatments for COVID-19. We aimed to evaluate the effects of Sugarcane, Black Myrobalan, and Mastic herbal medications for COVID-19 patients.
Methods This was a double-blinded randomized clinical trial study conducted over three months from May to July 2020 in patients admitted with a diagnosis of COVID-19 in Peymaniyeh Hospital in Jahrom, Iran. The intervention group received the treatment protocol approved by the Ministry of Health of Iran during the period of hospitalization and the herbal supplement obtained from the combination of black myrobalan and mastic and sugarcane, twice a day (3g of herbal supplements). All patients were compared in terms of demographic variables, vital signs, clinical and laboratory variables.
Results 72 patients with COVID-19, divided into intervention (n=37) and control (n=35) groups. intervention and control groups had not any significant difference in terms of baseline characteristics. The time-to-event analysis revealed a significant difference in 4 symptoms of cough, fever, dyspnea, and myalgia (P<0.05). The Control group had a significantly lower decrease in C-reactive protein during 7 days (P<0.05). Patients in the herbal supplement group were hospitalized for 4.12 days and in the control group were hospitalized for 8.37 days (P=0.001). ICU admission and death only happened in 3 (8.6%) patients of the control group.
Conclusion While advanced studies with more sample size are needed; the proposed combination seems to be effective in the symptom treatment and reducing the length of hospitalization.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
IRCT20200415047082N1
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committee of Jahrom University of Medical Sciences under the ethical code IR.JUMS.REC.1399.003 and was registered in the Iranian registry of clinical trials under the number IRCT20200415047082N1.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant and studied data are available in all versions of this manuscript.
Abbreviations
- ALT
- Alanine aminotransferase
- AHA
- American Heart Association
- AST
- Aspartate aminotransferase
- BUN
- Blood urea nitrogen
- BMI
- Body mass index
- Cr
- Creatinine
- DBP
- Diastolic blood pressure
- HB
- Hemoglobin
- INR
- International normalized ratio
- PTT
- Partial thromboplastin time
- PT
- Prothrombin time
- PR
- Pulse rate
- RBCS
- Red blood cells
- RR
- Respiratory rate
- SBP
- Systolic blood pressure
- TIM
- Traditional Iranian Medicine
- WBCS
- White blood cells
